Volume 62, Issue 6, Pages (December 2002)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Kamyar Kalantar-Zadeh Kidney International

Volume 62, Issue 2, Pages (August 2002)

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Plasma sodium and hypertension

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 86, Issue 1, Pages (July 2014)

Red blood cell life span and ‘erythropoietin resistance’

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Confounding: What it is and how to deal with it

Volume 63, Issue 6, Pages (June 2003)

Volume 72, Issue 8, Pages (October 2007)

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Volume 64, Issue 5, Pages (November 2003)

The risk of hospitalization and modality failure with home dialysis

Section 5: Dialysis Interventions for Treatment of AKI

Need for better diabetes treatment for improved renal outcome

Volume 62, Issue 2, Pages (August 2002)

Overcoming barriers that inhibit proper treatment of anemia

Kamyar Kalantar-Zadeh Kidney International

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Chapter 4: Red cell transfusion to treat anemia in CKD

Volume 65, Issue 3, Pages (March 2004)

Comorbidity and confounding in end-stage renal disease

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Darbepoetin alfa: A new therapeutic agent for renal anemia

Volume 70, Issue 11, Pages (December 2006)

Joseph W. Eschbach, John W. Adamson Kidney International

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Prevention of renal failure: The Malaysian experience

Volume 60, Issue 6, Pages (December 2001)

Volume 70, Issue 12, Pages (December 2006)

Blood pressure targets in hemodialysis patients

Volume 78, Issue 2, Pages (July 2010)

Arterial function after successful renal transplantation

Volume 68, Issue 6, Pages (December 2005)

Volume 87, Issue 1, Pages (January 2015)

Volume 70, Issue 7, Pages (October 2006)

Darbepoetin alfa (Aranesp™) in children with chronic renal failure

Francesco Locatelli, Lucia Del Vecchio Kidney International

Volume 66, Issue 2, Pages (August 2004)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 79, Issue 3, Pages (February 2011)

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Lynda Anne Szczech, Ira L. Lazar Kidney International

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Carmine Zoccali, Francesca Mallamaci Kidney International

The course of the remnant kidney model in mice

Does equal care give equal outcomes?

Volume 62, Issue 2, Pages (August 2002)

Volume 66, Issue 6, Pages (December 2004)

The Danish Renal Biopsy Register

Volume 83, Issue 4, Pages (April 2013)

Volume 64, Issue 5, Pages (November 2003)

American Indian heritage and risk factors for renal injury

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 66, Issue 2, Pages (August 2004)

Strategies for iron supplementation: Oral versus intravenous

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary

Stephen Pastan, J. Michael Soucie, William M. McClellan

Volume 68, Issue 4, Pages (October 2005)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 62, Issue 6, Pages 2167-2175 (December 2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients Yves Vanrenterghem, Peter Bárány, Johannes F.E. Mann, Peter G. Kerr, Janet Wilson, Nigel F. Baker, Stephen J. Gray Kidney International Volume 62, Issue 6, Pages 2167-2175 (December 2002) DOI: 10.1046/j.1523-1755.2002.00657.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Study design. Kidney International 2002 62, 2167-2175DOI: (10.1046/j.1523-1755.2002.00657.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Patients included in the analysis. *Includes all randomized patients who received at least one dose of the study drug. **Includes only patients who completed and had 6/8 hemoglobin assessments during the evaluation period; received the allocated study drug according to protocol; had no change to dialysis modality or route of study drug administration; and received no red blood cell transfusions during weeks 15–32 of study. Kidney International 2002 62, 2167-2175DOI: (10.1046/j.1523-1755.2002.00657.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Mean (± 2 SD) hemoglobin over time. Symbols are: (•) darbepoetin alfa (N = 347); (○) recombinant human erythropoietin (rHuEPO; N = 175). Whiskers denote standard deviation. Kidney International 2002 62, 2167-2175DOI: (10.1046/j.1523-1755.2002.00657.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Mean (95% CI) dose of study drug by route of administration. Symbols are: (▪) IV dosing; (□) SC dosing. Kidney International 2002 62, 2167-2175DOI: (10.1046/j.1523-1755.2002.00657.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Odds ratio (95% CI) between darbepoetin alfa and rHuEPO for adverse events occurring with a frequency of ≥10% in either treatment group. Kidney International 2002 62, 2167-2175DOI: (10.1046/j.1523-1755.2002.00657.x) Copyright © 2002 International Society of Nephrology Terms and Conditions